P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Darolutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): ARASEC – US prospective, open-label phase 2 study with an external control

P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Darolutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): ARASEC – US prospective, open-label phase 2 study with an external control

Friday, May 15, 2026 11:10 AM to 11:20 AM · 10 min. (America/New_York)
Hall D
Detail

Registered attendees

Ignacio Tobia Gonzalez
Ignacio Tobia Gonzalez
Associate Profesor Urology Department Hospital Italiano de Buenos AiresLatin Ametrican Renal Cancer Group
Mario Basultomartinez
Mario Basultomartinez
Clinical FellowHRAEPY-UNAM

Log in

See all the content and easy-to-use features by logging in or registering!